Login
Grifols SA NASDAQ: GRFS
Grifols SA is a Spain-based company engaged in the healthcare sector. The Company is involved in the research, development, manufacturing and marketing of medical solutions for hospitals, which include plasma-derived therapies, as well as diagnosis and pharmaceutical products
| Name | Grifols SA |
| Ticker | GRFS |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Drug Manufacturers - Diversified |
| Price | 18.98 |
| 52W Low/High | 15.40 / 25.63 |
| Market cap | 13 B |
| 1Y Total Return |
-16.85%
Weak |
| 1Y Volatility |
43.97%
Low Risk |
Relative Strength Index : Attempt to identify overbought (above 80) and oversold (below 20) conditions
Grifols SA is a Spain-based company engaged in the healthcare sector. The Company is involved in the research, development, manufacturing and marketing of medical solutions for hospitals, which include plasma-derived therapies, as well as diagnosis and pharmaceutical products
Details
| Ticker | GRFS |
| Name | Grifols SA |
| ISIN | US3984384087 |
| CUSIP | |
| Exchange | NASDAQ |
| Sector | Health Care |
| Industry | Drug Manufacturers - Diversified |
| Country | Spain |
| Currency | U.S. Dollar |
| In Index(ices) | NASDAQ Biotechnology Index |
Share as of 1/25/21
| Close Price | 18.98 |
| 52W Low/High | 15.40 / 25.63 |
| Market cap | 13 B |
| 1Y Total Return |
-16.85%
Weak |
| 1Y Volatility |
43.97%
Low Risk |
| Beta | 0.77 |
| PE (trailing) |
18.56
Below Average |
| 12M Dividends | 0.589888 |
| Last Dividend Date | 10/30/20 |
| Dividend Yield | 3.11% |
Fin. Strength
| Net Profit Margin | 12.3% |
| Cash from Op. / Cur. Liabilities | 0.42 |
| Diluted Earnings / Share | 1.02 |
| ROE | 13.7% |
| ROIC | 7.4% |
| Price / Revenue | - |
| Price / Book | - |
| Price / CF | - |
| Current Ratio | 3.9 |
| Cur.Liabilities / Tot.Liabilities | 0.2 |
| Financial Leverage | 1.49 |
| in Mils USD |
rolling-year up to December
|
||||||
|---|---|---|---|---|---|---|---|
| Income Statement | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
| Revenue |
5,729
|
5,157
|
5,184
|
4,263
|
4,272
|
3,604
|
|
| Gross Profit |
2,631
|
2,356
|
2,583
|
2,013
|
2,097
|
1,825
|
|
| R&D |
310
|
277
|
346
|
208
|
243
|
194
|
|
| EBITDA |
1,617
|
1,437
|
1,412
|
1,221
|
1,217
|
1,082
|
|
| Operating Income |
1,261
|
1,143
|
1,204
|
989
|
1,054
|
921
|
|
| Net Income exc. Extra |
702
|
686
|
796
|
574
|
578
|
505
|
|
| per Share | |||||||
| Diluted avg Shares |
-
|
-
|
-
|
-
|
-
|
-
|
|
| EPS exc. Extra |
1.02
|
1.00
|
1.16
|
0.84
|
0.85
|
0.74
|
|
| Dividend |
0.59
|
0.55
|
0.45
|
0.37
|
0.77
|
0.57
|
|
| Div. Yield (an.) |
2.25%
|
2.61%
|
1.64%
|
2.18%
|
4.40%
|
3.21%
|
|
| Balance Sheet | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
| Total Assets |
17,464
|
14,341
|
13,110
|
10,663
|
10,425
|
9,076
|
|
| Cash, Eq & Invt ShortTerm |
2,776
|
1,250
|
1,077
|
945
|
1,242
|
1,160
|
|
| Total Current Assets |
6,025
|
4,004
|
3,536
|
3,287
|
3,354
|
3,129
|
|
| Total Non-Current Assets |
11,439
|
10,338
|
9,574
|
7,376
|
7,071
|
5,947
|
|
| Intangibles |
7,798
|
7,580
|
7,035
|
5,094
|
5,097
|
4,558
|
|
| Total Liabilities |
9,772
|
8,943
|
8,747
|
6,739
|
6,841
|
6,216
|
|
| Total Current Liabilities |
1,535
|
1,445
|
1,174
|
1,128
|
1,143
|
1,160
|
|
| Long Term Debt |
8,236
|
7,498
|
7,573
|
5,611
|
5,697
|
5,056
|
|
| Shareholder equity |
5,418
|
4,857
|
4,357
|
3,917
|
3,579
|
2,855
|
|
| Cash Flow | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
| Cash from Operations |
639
|
848
|
1,010
|
582
|
806
|
1,051
|
|
| Depreciation |
340
|
263
|
259
|
212
|
206
|
204
|
|
| Cash from Investing |
-617
|
-899
|
-2,624
|
-533
|
-687
|
-1,634
|
|
| Capex |
809
|
620
|
689
|
568
|
1,168
|
546
|
|
| Cash from Financing |
-373
|
175
|
1,722
|
-347
|
-172
|
903
|
|
| Stock Issued |
0
|
0
|
0
|
-25
|
28
|
-149
|
|
| Debt (LT) Issued |
-8
|
43
|
2,171
|
-84
|
31
|
1,317
|
|
| Free Cash Flow |
11
|
574
|
382
|
206
|
-318
|
562
|
|
| Ratios | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
| Net Profit Margin |
12.3%
|
13.3%
|
15.3%
|
13.5%
|
13.5%
|
14.0%
|
|
| NCFO / Op.Income |
50.7%
|
74.2%
|
83.9%
|
58.9%
|
76.5%
|
114.1%
|
|
| Current Ratio |
3.9
|
2.8
|
3.0
|
2.9
|
2.9
|
2.7
|
|
| Financial Leverage D/E |
1.49
|
1.51
|
1.67
|
1.33
|
1.47
|
1.64
|
|
| Return on Capital Avg |
7.4%
|
8.5%
|
11.2%
|
9.3%
|
9.8%
|
10.9%
|
|
| Return on Shareholder Equity |
13.7%
|
14.9%
|
19.2%
|
15.3%
|
17.0%
|
17.6%
|
|
Fundamentals
No documents are available for the moment, please check back soon, or save the asset to be notified when documents are available